FDA chief looks to speed diabetes, obesity drugs
Mark McClellan, commissioner of the Food and Drug Administration, said he wants to apply a fast-track review process normally reserved for drugs for terminal cancer and AIDS patients to drugs for diabetes and obesity.
Pfizer sues over counterfeit Lipitor
Pfizer Inc. said Tuesday it was suing two companies connected to counterfeit versions of its cholesterol fighter, Lipitor, the world’s top-selling prescription medicine.
The ImClone Story: A Hyped Drug, a Tainted Icon
It was, in retrospect, a festival of hype emblematic of the boom years, when technology stocks seemed to have nowhere to go but up.
Five Hurdles for Biotech
The science is hot and the stocks are up. Here’s what’s needed to deliver on the promise.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments